These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance. Lane RJ; Roncaroli F; Charles P; McGonagle DG; Orrell RW Neuromuscul Disord; 2012 Feb; 22(2):122-8. PubMed ID: 21872471 [TBL] [Abstract][Full Text] [Related]
70. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584 [TBL] [Abstract][Full Text] [Related]
71. [Antibodies in myasthenia gravis]. Eymard B Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288 [TBL] [Abstract][Full Text] [Related]
72. [Myasthenia gravis induced by autoantibodies against MuSK]. Shigemoto K; Konishi T; Ohta M Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361 [TBL] [Abstract][Full Text] [Related]
73. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Atassi MZ; Oshima M; Deitiker P Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597 [TBL] [Abstract][Full Text] [Related]